본문 바로가기
KERD
논문KCI 등재

국내 사람유두종바이러스백신 접종 후 자발적 이상반응 보고사례의 Brighton Collaboration 기준 활용 가능성 연구

Patterns of Spontaneous Adverse Events Reporting on Human Papillomavirus Vaccines according to the Applicability of Brighton Collaboration Criteria in Korea from 2008 to 2017

강예진|유승훈|박혜민|정선영|이민택|구현지|김묘송
한국임상약학회 (Korean College Of Clinical Pharmacy)|2020.03|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제30권 제1호|pp. 19-30|DOI https://doi.org/10.24304/kjcp.2020.30.1.19

0

조회

0

다운로드

2

인용

0

참고문헌

키워드

safetyVaccineadverse event following immunizationhuman papilloma virusBrighton Collaboration
주제분류약학

초록

Objective: To describe patterns of spontaneous reporting on adverse events following immunization (AEFIs) using the human papilloma virus (HPV) vaccine according to the Brighton Collaboration (BC) criteria. Methods: We used the Korea Adverse Event Reporting System (KAERS) database including vaccinations between 2008 and 2017. To apply BC criteria, we classified 58 BC AEFIs into World Health Organization Adverse Reaction Terminology (WHO-ART) codes. We applied MedDRA standard medical queries that were pre-defined as five BC AEFIs. Terminology mapping between MedDRA and WHO-ART terms was performed by three researchers. Descriptive statistics of individual case safety reports were analyzed according to BC applicability. Disproportionality analyses were performed on each BC AEFI and each preferred AEFI term according to the case-noncase approach; reporting odds ratio (ROR) and 95% confidence intervals (CI) were calculated. Results: Among the 30,266 reports of vaccinations between 2008 and 2017, 2,845 reports included the HPV vaccine. Of these reports, 1,511 (53.1%) included at least one BC AEFI. Reports from physicians or manufacturers included more BC AEFIs than from other reporters. Injection site reactions and fever were frequently reported in BC AEFIs; spontaneous abortion and ectopic pregnancy (ROR, 14.29 [95% CI, 4.30-47.49]) and vasculitic peripheral neuropathy (ROR, 8.57 [95% CI, 2.61-28.10]) showed the highest ROR. Among non-BC AEFIs, dizziness or myalgia were frequently reported; exposure during pregnancy (ROR, 23.95 [95% CI, 16.27-35.25]) and inappropriate schedule of administration (ROR, 22.89 [95% CI, 16.74-31.31]) showed the highest ROR. Conclusion: BC criteria would be applicable for labeled AEFIs, whereas analyzing non-BC AEFIs would be useful for detecting unlabeled AEFIs.

Abstract

Objective: To describe patterns of spontaneous reporting on adverse events following immunization (AEFIs) using the human papilloma virus (HPV) vaccine according to the Brighton Collaboration (BC) criteria. Methods: We used the Korea Adverse Event Reporting System (KAERS) database including vaccinations between 2008 and 2017. To apply BC criteria, we classified 58 BC AEFIs into World Health Organization Adverse Reaction Terminology (WHO-ART) codes. We applied MedDRA standard medical queries that were pre-defined as five BC AEFIs. Terminology mapping between MedDRA and WHO-ART terms was performed by three researchers. Descriptive statistics of individual case safety reports were analyzed according to BC applicability. Disproportionality analyses were performed on each BC AEFI and each preferred AEFI term according to the case-noncase approach; reporting odds ratio (ROR) and 95% confidence intervals (CI) were calculated. Results: Among the 30,266 reports of vaccinations between 2008 and 2017, 2,845 reports included the HPV vaccine. Of these reports, 1,511 (53.1%) included at least one BC AEFI. Reports from physicians or manufacturers included more BC AEFIs than from other reporters. Injection site reactions and fever were frequently reported in BC AEFIs; spontaneous abortion and ectopic pregnancy (ROR, 14.29 [95% CI, 4.30-47.49]) and vasculitic peripheral neuropathy (ROR, 8.57 [95% CI, 2.61-28.10]) showed the highest ROR. Among non-BC AEFIs, dizziness or myalgia were frequently reported; exposure during pregnancy (ROR, 23.95 [95% CI, 16.27-35.25]) and inappropriate schedule of administration (ROR, 22.89 [95% CI, 16.74-31.31]) showed the highest ROR. Conclusion: BC criteria would be applicable for labeled AEFIs, whereas analyzing non-BC AEFIs would be useful for detecting unlabeled AEFIs.

참고문헌 (34)

  1. Frazer IH, "Prevention of cervical cancer through papillomavirus vaccination", Nat Rev Immunol, 4(1), pp.46~55 (2004)
  2. "Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations", Vaccine, 35(43), pp.5753~5755 (2017)
  3. Sutton I, "CNS demyelination and quadrivalent HPV vaccination", Mult Scler, 15(1), pp.116~119 (2009)
  4. Yonee C, "Association of Acute Cerebellar Ataxia and Human Papilloma Virus Vaccination : A Case Report", Neuropediatrics, 44(05), pp.265~267 (2013)
  5. Tomljenovic L, "Death after quadrivalent human papillomavirus(HPV)vaccination : causal or coincidental", Pharmaceut Reg Affairs S, 12, pp.2~ (2012)
  6. "Vaccine safety basics e-learning course"[URL]
  7. "Definition and application of terms for vaccine pharmacovigilance;Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance"[URL]
  8. "Guideline on good pharmacovigilance practices (GVP); Product- or Population-Specific Considerations I:Vaccines for prophylaxis against infectious diseases"[URL]
  9. Leroy Z, "Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system", Vaccine, 30(11), pp.2020~2023 (2012)
  10. Slade BA, "Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine", JAMA, 302(7), pp.750~757 (2009)
  11. Choe YJ, "Guillain–Barré syndrome following receipt of influenza A(H1N1)2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition", Vaccine, 29(11), pp.2066~2070 (2011)
  12. "Introductory Guide for Standardised MedDRA Queries (SMQs) Version 22.1"[URL]
  13. van Puijenbroek EP, "A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions", Pharmacoepidemiol Drug Saf, 11(1), pp.3~10 (2002)
  14. Faillie JL, "Case-non-case studies: Principle, methods, bias and interpretation", Therapie, 74(2), pp.225~232 (2019)
  15. Scotti L, "Should methods of correction for multiple comparisons be applied in pharmacovigilance", Epidemiol Biostat Public Health, 12(4), pp.e11654~ (2015)
  16. "Ministry of Food and Drug Safety"[URL]
  17. Gidudu J, "A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data", Vaccine, 26(52), pp.6800~6813 (2008)
  18. Zhou W, "Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001", MMWR Surveill Summ, 52(1), pp.1~24 (2003)
  19. "<Amended Sep. 27, 2019>"[URL]
  20. Kharbanda EO, "Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy", Obstet Gynecol, 132(1), pp.35~44 (2018)
  21. Geier DA, "A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events", Clin Rheumatol, 34(7), pp.1225~1231 (2015)
  22. Melo Gomes S, "Vasculitis following HPV immunization", Rheumatology, 52(3), pp.581~582 (2012)
  23. Chandler RE, "Current safety concerns with human papillomavirus vaccine : a cluster analysis of reports in VigiBase®", Drug Saf, 40(1), pp.81~90 (2017)
  24. Brinth LS, "Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus", Vaccine, 33(22), pp.2602~2605 (2015)
  25. Kinoshita T, "Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine", Intern Med, 53(19), pp.2185~2200 (2014)
  26. "Safety update of HPV vaccines"[URL]
  27. "Korea Centers for Disease Control and Prevention"[URL]
  28. Hibbs BF, "Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013", Vaccine, 33(28), pp.3171~3178 (2015)
  29. Goss MA, "Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine", Vaccine, 33(29), pp.3422~3428 (2015)
  30. Top KA, "Applicability of the Brighton Collaboration case definition for seizure after immunization in active and passive surveillance in Canada", Vaccine, 31(48), pp.5700~5705 (2013)
  31. "Reporting Adverse Events Following Immunization (AEFI) in Canada: User Guide to completion and submission of the AEFI reports 2019"[URL]
  32. Law BJ, "Canadian Adverse Events Following Immunization Surveillance System(CAEFISS) : Annual report for vaccines administered in 2012", Can Commun Dis Rep, 40(Suppl 3), pp.7~23 (2014)
  33. Bate A, "Quantitative signal detection using spontaneous ADR reporting", Pharmacoepidemiol Drug Saf, 18(6), pp.427~436 (2009)
  34. 정수연, "의약품 안전관리 선진화를 위한 한국의약품안전관리원의 역할", 대한의사협회지, 55(9), pp.861~868 (2012), 대한의사협회

이 간행물의 다른 논문 (7건)

메타분석을 이용한 호르몬 수용체 양성/인체 상피세포 성장 인자 수용체 음성 진행성 유방암에서 사이클린 의존성 인산화효소 4/6 억제제와 방향화효소 억제제 병용요법과 방향화효소 억제제 단독요법의 임상적 유효성 및 안전성 비교 연구김경, 김민지, 조문경, 손기호, 백인환pp. 1-10고령 암환자에서의 nivolumab과 pembrolizumab의 유효성과 안전성 평가심미경, 김혜성, 정효근pp. 11-18HMG CoA-reductase inhibitors를 복용하는 환자의 잠재적 약물상호작용 연구이경주, 이유정, 유승완, 정예지, 남기남, 성재민, 김경림, 조세경, 이현윤pp. 31-35The Effects of Intrapatient Variability in Tacrolimus Concentration on Clinical Outcomes Immediately After Liver Transplantation김보람, 조재영, 유윤미, 김은지, Eunkyung Euni Lee, 조정원, 최영록, 이은숙, 이정화pp. 36-43타이로신키나아제 억제제의 임상적으로 유의한 약물상호작용 정보 일관성 분석안슬기, 아영미, 이주연pp. 44-50
원문 보기